Myocarditis is generally a mild and self-limited consequence of systemic infection of
cardiotropic viruses. However, patients can develop a temporary or permanent impairment …

Background: To investigate the clinical features of cardiac involvement in polymyositis (PM)
or dermatomyositis (DM). Hypothesis: More attention will be focused on the heart in PM/DM …

Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with
myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in …

Idiopathic inflammatory myopathies (IIM) include the main subgroups polymyositis (PM),
dermatomyositis (DM), inclusion body myositis (IBM) and juvenile DM (JDM). The mentioned …

OBJECTIVE: To report our experience using rituximab as therapy for refractory
antisynthetase syndrome (ASS)-associated interstitial lung disease. METHODS: We …

High-dose oral prednisone (at an initial dose of 1mg/kg/day) is the mainstay of therapy for
PM/DM, and should be subsequently tapered slowly based on patients' clinical response …

Although rheumatologists, neurologists and dermatologists see patients with polymyositis
(PM) and dermatomyositis (DM), their management appears to vary depending on the …

Idiopathic inflammatory myopathies are a group of autoimmune diseases that are
characterized by muscle inflammation resulting in elevated muscle enzyme release and …

Objective. To evaluate the safety and efficacy of rituximab (RTX) in juvenile dermatomyositis
(JDM) in off-trial patients. Methods. We conducted a multicenter prospective study of patients …

Rituximab (Mabthera, Rituxan) is a chimeric human/murine monoclonal antibody against CD-
20 surface antigen expressed on B-cells. Rituximab, by causing B-cell depletion, appears to …